Search the Newsreel

Telos (NASDAQ:TLS) Director Derrick Dockery Sells 11,000 Shares of Stock

Telos Director Derrick Dockery recently sold 11,000 shares of the company's stock for $47,740, reducing his direct ownership by 6.13%. This transaction follows Telos's positive quarterly earnings report, where the company beat EPS and revenue estimates, causing its shares to rise by 6.0%. Despite …

Artelo Biosciences Releases Q2 2026 Financial Results

Artelo Biosciences, Inc. reported a net loss of $2.4M and a loss of $0.89 per share for Q2 2026, marking a significant improvement from the $16.8 per-share loss in Q2 2025. The clinical-stage biopharmaceutical company continues to advance its therapeutic pipeline targeting lipid-signaling pathways, …

Artelo Plans Q4 Trial After ART26.12 Matches Naproxen for Pain

Artelo Biosciences reported its Q2 2026 financial results, with a narrowed net loss of $2.4 million and positive pipeline updates. The company plans a Phase 1 multiple ascending dose study for ART26.12 in Q4 2026, which has shown pain relief comparable to naproxen in …

Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed a 4.8% beneficial ownership stake in Artelo Biosciences (ARTL) through a warrant held by Intracoastal. This ownership amounts to 173,914 shares of common stock, issuable upon the warrant's exercise, and is based …

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

Artelo Biosciences Clinical and Scientific Progress Across the Pipeline Supports Multiple Upcoming Milestones SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for …

Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss

Artelo Biosciences reported a net loss of $5.4 million for the first half of 2026 but significantly improved its liquidity and balance sheet. The company increased cash and cash equivalents to $4.2 million from $0.6 million at year-end 2025 and reduced total liabilities from …

Tellus (TLS) investor Derrick Dockery files to sell 11,000 shares

Derrick Dockery, an investor in Tellus (TLS), has filed a Form 144 notice to sell 11,000 shares of common stock through Morgan Stanley Smith Barney LLC. The aggregate market value of this planned transaction is $47,737.80, with a proposed sale date of August 12, …

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% - Should You Sell?

Telos Corporation (TLS) stock price, news, quote and history

This article provides comprehensive financial data for Telos Corporation (TLS), including its current stock price, market performance, and key financial metrics. It also offers an overview of the company's business segments, recent news, analyst insights, and comparisons with similar companies in the software infrastructure …

D.A. Davidson holds Telos stock rating at Neutral on margin outlook

D.A. Davidson has maintained a Neutral rating and $4.00 price target for Telos Corp. following the company's Q2 results. While Telos exceeded revenue and EBITDA estimates and raised its 2026 EBITDA guidance, it lowered its 2026 revenue guidance due to phasing out low-margin third-party …

Telos earnings beat by $0.02, revenue topped estimates

Telos (NASDAQ: TLS) reported strong second-quarter results, beating analyst estimates for both EPS and revenue. The company posted an EPS of $0.040, exceeding the $0.021 estimate, and revenue of $47.75 million, higher than the $45.07 million consensus. Telos's stock has shown positive performance, rising …

Telos Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TLS) 2026-08-11

Telos Corp (TLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 33% and Adjusted EBITDA ...

Telos Corp (TLS) reported strong Q2 2026 earnings, with revenue increasing 33% year-over-year to $47.7 million and Adjusted EBITDA reaching $6.9 million, both exceeding guidance. The company also generated $6.6 million in free cash flow and repurchased over 1 million shares. Despite some expected …

Artelo Biosciences Enrolls First Patient In Phase 2 Glaucoma Study Of ART27.13

(RTTNews) - Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company focused on lipid-signaling pathways, announced the enrollment of the first patient in the Phase 2 DREAM study evaluating ART27.13 in patients with glaucoma or ocular hypertension. The investigator-led DREAM study is designed to evaluate …

TLS Looks 3.4% Undervalued on GF Value™ at $4.25

Telos Corporation (TLS) recently reported strong quarterly results with a 33% year-over-year revenue increase and better-than-expected profitability. Despite trading slightly below its GF Value™ estimate, suggesting modest undervaluation, the company faces skepticism due to its unprofitable status. TLS has a moderate GF Score™ of …

Artelo Enrolls First Patient In Phase 2 DREAM Trial For ART27.13 In Treating Intralocular Pressure

(RTTNews) - Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Monday announced the enrollment of the first patient in the Phase 2 DREAM trial for ART27.13 in treating glaucoma or ocular hypertension. Glaucoma affects about 80 million people worldwide and often leads to …

Telos Q2 Earnings Call Highlights

Key Points Interested in Telos Corporation? Here are five stocks we like better. Telos exceeded Q2 expectations: Revenue rose 33% year over year to $47.7 million, while adjusted EBITDA reached $6.9 million, well above guidance. Stronger Telos ID performance, including TSA PreCheck, helped drive …

Earnings call transcript: Telos tops Q2 2026 revenue guidance, shares fall 12.8%

Telos Corporation reported Q2 2026 revenue of $47.7 million, exceeding guidance, and adjusted EBITDA of $6.9 million, also above expectations. Despite strong performance driven by TSA PreCheck and DMDC programs, shares fell 12.8% due to softer third-quarter guidance and a lowered full-year revenue outlook, …

Telos Corporation (TLS) Q2 Earnings and Revenues Beat Estimates

Telos (NASDAQ:TLS) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Telos (NASDAQ:TLS) recently released its quarterly earnings, reporting an EPS of $0.04, which surpassed the consensus estimate of $0.02. The company also exceeded revenue expectations, bringing in $47.75 million against an anticipated $45.16 million, though it remained unprofitable with a negative net margin. Despite …

Form 8K Telos Corp For: 10 August By Investing.com

This article announces the filing of a Form 8K by Telos Corp on August 10th. The brief piece primarily serves as a news alert, directing readers to the Form 8K filing for detailed information.

Artelo Tests an Oral Cannabinoid for Glaucoma Eye Pressure

Artelo Biosciences has dosed the first patient in its Phase 2 DREAM study, evaluating the oral synthetic cannabinoid ART27.13 for glaucoma and ocular hypertension. The study, funded by Glaucoma UK and HSC R&D Division and led by Professor Augusto Azuara-Blanco, aims to assess ART27.13's …

Telos Corporation (TLS) swings to Q2 profit with 33% revenue growth and higher 2026 EBITDA outlook

Telos Corporation reported strong Q2 2026 results, swinging to a GAAP net income of $0.7 million from a $9.5 million loss a year prior, with revenue increasing by 33% to $47.7 million. The company's Adjusted EBITDA rose significantly to $6.9 million, expanding its margin …

Telos Corporation Announces Second Quarter 2026 Earnings

Telos Corporation (NASDAQ: TLS) has announced its second quarter 2026 financial results, which have been posted on its investor relations website. The company will host a live webcast on August 10, 2026, at 9:30 a.m. ET to discuss these results, with an archived webcast …

Antelopus Selan Energy reshapes board committees after independent director exits

Price to sales forward of Artelo Biosciences, Inc. – NASDAQ:ARTL

This article displays the "Price to sales forward" metric for Artelo Biosciences, Inc. (NASDAQ: ARTL) on the TradingView platform. It provides financial data for the company, noting the market is currently closed with no trades. The primary content is a financial data point for …

Enterprise value to revenue forward of Artelo Biosciences, Inc. – NASDAQ:ARTL

Telos Corp (TLS) Stock News Today

This article from TradingKey provides current stock information for Telos Corp (TLS), including its stock price, market cap, and performance metrics. It notes that more news is coming soon for Telos Corp, covering earnings, analyst ratings, and key developments. The page is primarily a …

Telos Corp expected to post earnings of 2 cents a share - Earnings Preview

Telos Corp is projected to report earnings of 2 cents per share. This article is an earnings preview indicating the expected financial performance for the company. The full article is available on TradingView, providing access to Reuters and other news sources.

Earnings To Watch: Telos Corp (TLS) Q2 2026 -- GF Value Sees 10% Upside

Telos Corp (TLS) is scheduled to release its Q2 2026 earnings on August 10, 2026, with revenue estimated at $45.17 million and earnings at -$0.02 per share. Analyst price targets suggest a potential upside of 49.20%, while GuruFocus's GF Value indicates a 10.48% upside. …

Telos Q2 2026 Earnings Preview

* Telos (TLS [https://seekingalpha.com/symbol/TLS]) is scheduled to announce Q2 earnings results on Monday, August 10th, before market open. * The consensus EPS Estimate is $0.02 [https://seekingalpha.com/symbol/TLS/earnings/estimates] (+166.7% Y/Y) and the consensus Revenue Estimate is $45.17M (+25.6% Y/Y). * Over the last 2 years, TLS …

Telos Corp (TLS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Telos Corp (TLS), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that analysts have a "Buy" trend for TLS, with expected revenue of $45.17M for the next quarter and an EPS …

Telomir Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Aminov Erez

This article is a filing document from Telomir Pharmaceuticals, specifically a Statement of changes in beneficial ownership of securities. It concerns Officer Aminov Erez and details modifications to their security holdings within the company.